Publications by authors named "Rincheval N"
Article Synopsis
- The study aimed to assess the effectiveness of the DAS28 γ-glutamyl transferase (DAS28-γGT) in predicting major cardiovascular events (MACE) in patients with rheumatoid arthritis (RA) from the ESPOIR cohort over 13 years.
- Out of 696 RA patients, 34 experienced MACE, with a DAS28-γGT score above 9.4 being a strong indicator of higher risk, showing a hazard ratio of 3.11.
- The findings suggest that DAS28-γGT is a valuable and straightforward tool for evaluating cardiovascular risk in RA patients, helping clinicians better identify those at potential risk for MACE.
Article Synopsis
- Diethylstilbestrol (DES) is a synthetic estrogen linked to adverse health effects in mothers, their children, and grandchildren due to its ability to cross the placenta and disrupt endocrine function.
- A nationwide observational study analyzed data from 529 families of DES-treated women, focusing on pregnancy outcomes and birth weight variations across multiple generations.
- Results showed that preterm birth rates increased significantly in children exposed to DES, but those born post-DES had a higher average birth weight compared to pre-DES neonates, with some slight increases in low birth weight among grandchildren of DES-exposed women.
Article Synopsis
- The study aimed to explore how social support, financial status, and lifestyle choices affect the level of disability in individuals with rheumatoid arthritis (RA).
- Data were collected from the ESPOIR cohort, analyzing various factors like exercise, education, and financial situation to identify those with "excess disability."
- Results showed that lower social support, worse financial conditions, less exercise, and lower education levels significantly correlated with higher disability, emphasizing the need for better economic and social support for RA patients.
Article Synopsis
- The study aimed to assess the predictive value of PROS (protein S) and CO7 (complement component C7) for response to methotrexate (MTX) and etanercept (ETA) treatment in rheumatoid arthritis (RA) patients.
- RA patients from the ESPOIR cohort who received MTX with either ETA or adalimumab (ADA) were evaluated, measuring serum levels of PROS and CO7 before treatment.
- Results showed that higher levels of PROS were associated with better response rates to MTX/ETA, making it a potential biomarker for predicting treatment effectiveness in this patient group.
Article Synopsis
- The study aimed to identify different groups of people with rheumatoid arthritis (RA) who experience varying levels of disability over 10 years, even if their inflammation levels are similar.
- Data was collected from three European cohorts involving around 2500 participants, focusing on their disability (HAQ) and inflammation (DAS28-2C), as well as other factors like pain and mood.
- The findings indicated that while inflammation control is important, it may not be enough to reduce disability for everyone with RA; addressing pain, fatigue, and mental health may be crucial for improving long-term functionality.
Article Synopsis
- * At the 10-year mark, a significant portion of patients achieved various forms of remission, with 52.4% in DAS28 remission and only 6.5% requiring major joint surgery, indicating a mild overall outcome.
- * The findings suggest that the current patient cohort had better outcomes compared to older cohorts, likely due to more intensive treatment approaches available in recent years.
Article Synopsis
- The study aimed to investigate the long-term tolerability of glucocorticoids (GC) in patients with early rheumatoid arthritis (RA) over a 10-year period.
- Out of 608 patients analyzed, those who received low-dose GC experienced significantly more severe events such as deaths, cardiovascular diseases, and infections compared to those who did not receive GC.
- The risk of severe outcomes increased with higher cumulative doses of GC over time, indicating a concerning long-term impact of this treatment.
Objective: To determine, in a cohort of patients with early rheumatoid arthritis (RA), factors associated with fatigue at baseline, describe its evolution over 5 years of follow-up, and determine baseline predictors of persistent fatigue.
Method: We selected patients fulfilling the 2010 American College of Rheumatology/European League Against Rheumatism criteria for RA included in the ESPOIR cohort. Using bivariable and multivariable logistic regression models, we examined baseline variables associated with baseline fatigue (defined by visual analogue scale fatigue > 20) and baseline predictors of persistent fatigue (if the patient experienced fatigue at all visits during the 5 year follow-up period).
Article Synopsis
- The study aimed to investigate how baseline levels of vitamin D affect disease activity, disability, and joint damage in patients with early rheumatoid arthritis (RA) over the first year.
- Researchers analyzed data from 645 RA patients in the ESPOIR cohort, categorizing vitamin D levels into deficient, low, and normal groups.
- Results showed that vitamin D deficiency was linked to higher disease activity and disability scores initially and may predict worsening outcomes over 12 months.
Article Synopsis
- - The study aimed to analyze the disease progression in early arthritis patients who tested negative for rheumatoid factor and anti-citrullinated protein antibodies over a three-year period, focusing on predicting their classification as rheumatoid arthritis (RA) patients.
- - Results showed that a significant majority of seronegative patients met RA classification criteria by the end of the study, exhibiting lower disease activity scores and less joint damage compared to seropositive patients.
- - Key predictors for RA classification in seronegative patients included joint involvement, history of pain, morning stiffness, and number of tender joints, along with the presence of a triggering event indicating inflammation.
Article Synopsis
- Methotrexate (MTX) is the primary treatment for rheumatoid arthritis (RA), but its usage and dosages vary widely, leading to suboptimal treatment outcomes.
- A study evaluated the effectiveness of optimal MTX dosing in early RA patients over two years, highlighting that only 26.4% received the recommended dosage, defined as at least 10 mg/week initially and 20 mg/week after 6 months.
- Results showed that patients on optimal MTX doses had significantly better chances of achieving remission and improved functioning after one and two years, with no effect on joint damage progression.
Article Synopsis
- The study aimed to assess the long-term safety of glucocorticoids (GC) in patients with early rheumatoid arthritis (RA) over a 7-year period.
- It analyzed data from 602 RA patients, comparing those treated with low-dose GC to those who were not, focusing on serious health outcomes like death, heart disease, severe infections, and fractures.
- Results indicated that while there were a higher number of infections in the GC group, overall health outcomes showed no significant differences between patients receiving GC and those not receiving it, suggesting a favorable safety profile for low-dose GC in early RA treatment.
Article Synopsis
- Reduction of LDL-cholesterol (LDLc) is crucial to lower cardiovascular mortality in rheumatoid arthritis (RA), and guidelines implemented between 2006 and 2010 aimed to address this by identifying RA as an additional risk factor.
- A study analyzed data from 814 patients at high risk for RA and found that 77% were female, with a small percentage using statins to manage cholesterol levels.
- Despite the guidelines, the number of patients reaching the LDLc target worsened from 2006 to 2010, especially among those at the highest cardiovascular risk, indicating that management of dyslipidaemia remains inadequate in practice.
Article Synopsis
- The study aimed to determine if patients with rheumatoid arthritis (RA) who also exhibit fibromyalgic characteristics (FRA) respond differently to treatment compared to those with RA alone, using standard disease activity measures.
- Researchers analyzed data from 813 early arthritis patients, focusing on 697 classified as RA, comparing those with FRA (120 patients) to those without (548 patients) over 6, 12, and 18 months.
- Results showed that patients with FRA had higher disease activity scores and were less likely to reach low disease activity or remission, indicating that although treatment response improved for both groups, FRA patients struggled to meet treatment targets.
Early lessons from the recent-onset rheumatoid arthritis cohort ESPOIR.
Joint Bone Spine
January 2015
Article Synopsis
- ESPOIR is a French research cohort that studied patients with undifferentiated arthritis recruited within six months of symptoms, focusing on those at risk for developing rheumatoid arthritis (RA).
- Enrolled from December 2002 to March 2005, 813 patients were included from 14 hospitals, aimed at creating a comprehensive database for studying inflammatory joint diseases and RA.
- A decade later, about 500 patients remain in the study, with 104 research projects approved and 54 articles published, exploring various topics like diagnosis, treatment, and the impact of environmental factors on RA.
Article Synopsis
- The study investigates psychological distress in patients with very early rheumatoid arthritis (RA) and identifies factors contributing to depression and anxiety.
- Conducted within the ESPOIR cohort, 641 RA patients were assessed for psychological distress over three years using a mental health questionnaire.
- Results showed that nearly half of the patients experienced distress at the start, but this decreased over time, with disability levels (HAQ-DI score) being the key predictor for ongoing psychological issues.
Article Synopsis
- The study aimed to analyze the clinical and biological differences in early arthritis patients based on their rheumatoid factor (RF) and anti-cyclic citrullinated peptide antibodies (anti-CCP) status.
- The research involved 813 patients experiencing joint inflammation, categorizing them into four groups based on their serologic tests, and comparing their health features over time.
- Results indicated that patients with anti-CCP positivity showed significantly higher inflammation markers and radiographic progression, suggesting that this serologic profile may indicate a more aggressive form of early arthritis despite similar clinical presentations across groups.*
Article Synopsis
- - The study aimed to assess how common early remission is in different types of early arthritis and to identify factors that predict sustained remission over time.
- - Researchers analyzed data from 819 patients, revealing varying early remission rates depending on the criteria used—29.2% for rheumatoid arthritis (RA) by DAS28, and lower rates by other criteria.
- - Key predictors for sustained remission included lower disease activity scores, younger age, and non-menopausal status, showing consistent results across different definitions of remission.
Article Synopsis
- The study followed 813 patients with very early rheumatoid arthritis over 5 years to assess their outcomes and identify predictive factors.
- Most patients had mild disease activity and disability, with a significant number achieving remission or low disease activity by the end of the study.
- Anti-CCP antibodies were found to be strong predictors of positive outcomes, suggesting that early referral and effective treatment play crucial roles in managing RA.
Objective: To investigate the initial response to treatment and risk of radiographic disease progression in current smokers (S), ex-smokers (EX), and nonsmokers (NS) in a prospective early arthritis cohort and to analyze the influence of smoking cessation on arthritis outcome.
Methods: The ESPOIR cohort is a prospective cohort study monitoring clinical, biologic, and radiographic data for patients with inflammatory arthritis lasting 6 weeks to 6 months. We examined the influence of smoking status on disease presentation (baseline characteristics) and therapeutic response at 1 year.
Article Synopsis
- The study aimed to evaluate how well the 2010 ACR/EULAR criteria for diagnosing rheumatoid arthritis (RA) agree with a rheumatologist's diagnosis and other previous criteria used for classifying arthritis.
- Using a nationwide cohort of patients with recent-onset arthritis, the researchers found that after two years, about 79% of the patients had persistent arthritis, with most receiving disease-modifying antirheumatic drugs (DMARDs).
- The agreement between the various classification criteria was generally poor, except for cases where a rheumatologist's diagnosis had more than 50% certainty, which aligned well with the 2010 criteria, indicating these are reliable classification standards after two years.
Article Synopsis
- - This study focuses on defining rheumatoid arthritis (RA)-specific erosiveness based on radiographic analysis of early arthritis patients, using data from 980 Dutch and 811 French patients.
- - Researchers assessed how the number of erosive joints correlates with treatment initiation (methotrexate or other DMARDs) and long-term arthritis persistence while finding high specificity for various cut-off points of erosive joints.
- - The findings indicate that RA-specific erosiveness can be effectively defined, leading to further development of a definitive radiological criterion in the next phase of the research.
Article Synopsis
- The study evaluates the validity of the American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) remission definitions for rheumatoid arthritis (RA) using data from an observational study cohort, comparing those in remission to those not in remission.
- Researchers utilized a matching approach and bootstrap resampling to gather data, finding that ACR/EULAR defined remission showed a strong predictive ability for later disease stability based on x-ray and health assessments.
- The findings suggest that the remission definitions established from clinical trials are also applicable in real-world settings, indicating their potential for practical use in managing RA.